Research graph
References from No Longer a Luxury? MRD Dynamics as the Final Arbitrator for Cure in Locally Advanced NSCLC. Local targets link to admitted publications; unresolved targets remain external evidence.
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Treatment characteristics and real-world progression-free survival in patients with unresectable Stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study
10.1016/j.jtho.2022.10.003 · 2023 · External reference
ctDNA-Based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
10.1016/j.jtho.2026.103992 · 2026 · External reference
Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis
2025 · External reference
CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC
2024 · External reference
10.1016/j.annonc.2025.09.081
10.1016/j.annonc.2025.09.081 · 2025 · External reference
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
10.1080/14796694.2024.2354160 · 2024 · External reference
Rationale and design of the Phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for Stage III non-small-cell lung cancer
10.1016/j.cllc.2022.04.003 · 2022 · External reference
De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?
10.1200/jco-24-02347 · 2025 · External reference
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study
10.1371/journal.pmed.1004574 · 2025 · External reference
First-line camizestrant for emerging ESR1-mutated advanced breast cancer
10.1056/nejmoa2502929 · 2025 · External reference
